Kevin Michael O'Neill
Known title: CEO, PDxCIK: 0001951605
Associated companies
Transaction History
| GEHC | ▼ Sell | Tax Withholding | 718 | $51K | 9/3/2026 | View on chart |
| GEHC | ▲ Buy | Grant | 6,549 | $0 | 3/2/2026 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 3,261 | $258K | 2/12/2026 | View on chart |
| GEHC | ▲ Buy | Grant | 6,938 | $0 | 2/12/2026 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 462 | $36K | 2/1/2026 | View on chart |
| GEHC | ▲ Buy | Grant | 4,626 | $0 | 3/3/2025 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 1,521 | $133K | 3/1/2025 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 2,140 | $187K | 3/1/2025 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 462 | $41K | 2/1/2025 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 1,533 | $128K | 8/3/2024 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 2,140 | $195K | 3/1/2024 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 3,059 | $279K | 3/1/2024 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 1,717 | $157K | 3/1/2024 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 1,309 | $119K | 3/1/2024 | View on chart |
| GEHC | ▲ Buy | Grant | 3,235 | $0 | 3/1/2024 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 1,532 | $117K | 8/3/2023 | View on chart |
| GEHC | ▼ Sell | Open Market | 2,334 | $179K | 7/31/2023 | View on chart |
| GEHC | ▲ Buy | Option Exercise | 13,275 | $536K | 7/31/2023 | View on chart |
| GEHC | ▼ Sell | Open Market | 13,275 | $1.0M | 7/31/2023 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 763 | $57K | 3/2/2023 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 1,309 | $99K | 3/1/2023 | View on chart |
| GEHC | ▲ Buy | Grant | 3,652 | $0 | 3/1/2023 | View on chart |
| GEHC | ▲ Buy | Grant | 6,507 | $0 | 2/9/2023 | View on chart |
| GEHC | ▲ Buy | Grant | 1,964 | $0 | 2/1/2023 | View on chart |
| GEHC | ▲ Buy | Grant | 59 | — | 1/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
GEHC Secures CE Mark for MINItrace Magni Cyclotron
GE HealthCare (GEHC) has received CE approval for its MINItrace Magni cyclotron, expanding its PETtrace™ solid‑target platform to include copper‑64. The approval follows research showing its End‑tial Control software can reduce fresh gas flow in anesthesia settings. In addition, HeartBeam has joined a European consortium to develop at‑home ECG monitoring for early detection of acute coronary syndrome. These developments broaden GEHC’s product portfolio and support its investment narrative.
GEHC Secures CE Mark for MINItrace Magni Cyclotron. GE HealthCare (GEHC) has received CE approval for its MINItrace Magni cyclotron, expanding its PETtrace™ solid‑target platform to include copper‑64. The approval follows research showing its End‑tial Control software can reduce fresh gas flow in anesthesia settings. In addition, HeartBeam has joined a European consortium to develop at‑home ECG monitoring for early detection of acute coronary syndrome. These developments broaden GEHC’s product portfolio and support its investment narrative.